治疗中期表观扩散系数值在预测局部晚期宫颈癌放疗疗效中的价值
研究纳入80例经病理确诊的宫颈鳞状细胞癌并接受放疗的局部晚期宫颈癌患者,于放疗前、放疗开始后三周及放疗结束后约两个月行腹盆腔MRI并计算ADC值。结果显示,疗效差组的中期ADC、ΔADC和Δ%ADC均显著低于疗效好组,多因素logistic回归提示基线肿瘤直径与中期ADC是放疗疗效的显著预后因素。
要点
- 疗效差组的中期ADC、ΔADC和Δ%ADC均显著低于疗效好组(均P<0.05)。
- 中期ADC、ΔADC、Δ%ADC鉴别疗效的ROC最佳截断值分别为1.067×10-3 mm2/sec、0.209×10-3 mm2/sec和30.74%。
- 多因素logistic回归示基线肿瘤直径与中期ADC为放疗疗效的显著预后因素。
核心结论
- 中期ADC值和基线肿瘤直径可能是预测局部晚期宫颈癌患者放疗疗效的指标。
研究设计与样本
- 研究纳入80例经病理确诊的宫颈鳞状细胞癌并接受放疗的局部晚期宫颈癌患者。
- 所有参与者至少行三次腹盆腔MRI:放疗前、放疗开始后三周及放疗结束后约两个月。
- 计算ADC值包括pre-ADC、interim-ADC、ΔADC和Δ%ADC,依据RECIST 1.1分为疗效好组(完全缓解)和疗效差组(疾病进展、疾病稳定或部分缓解)。
主要发现
- 与疗效好组相比,疗效差组的中期ADC、ΔADC和Δ%ADC值显著更低(均P<0.05)。
- 中期ADC、ΔADC、Δ%ADC鉴别疗效好与疗效差的ROC最佳截断值分别为1.067×10-3 mm2/sec、0.209×10-3 mm2/sec和30.74%,对应灵敏度分别为83.78%、86.49%、75.68%,特异度分别为88.37%、86.49%、75.68%。
- 多因素logistic回归显示,基线肿瘤直径的OR为0.105(95%CI 0.018-0.616),中期ADC的OR为42.896(95%CI 8.205-224.262),均为放疗疗效的显著预后因素。
关键数值与推荐
- 中期ADC鉴别疗效好与疗效差的ROC最佳截断值为1.067×10-3 mm2/sec,灵敏度83.78%,特异度88.37%。
- ΔADC鉴别疗效好与疗效差的ROC最佳截断值为0.209×10-3 mm2/sec,灵敏度86.49%,特异度86.49%。
- Δ%ADC鉴别疗效好与疗效差的ROC最佳截断值为30.74%,灵敏度75.68%,特异度75.68%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For locally advanced cervical cancer (LACC), treatment response to radiotherapy (RT) can vary significantly even among those with the same stage classification of International Federation of Gynecology and Obstetrics (FIGO). This study investigated the value of ADC metric for forecasting end-of-treatment outcomes in LACC patients referred for RT. METHODS: Eighty patients with pathologically confirmed cervical squamous cell carcinoma with (SCC) were included in the research. Abdominal or pelvic MRI scans were conducted at least three times for all participants: before RT, three weeks after beginning of RT and approximately two months after RT was finalized. Calculated apparent diffusion coefficient (ADC) values of the LACC include: pre-ADC, interim-ADC, ΔADC and Δ%ADC. Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, subjects were calculated and subsequently categorized into good responders group (complete response) and poor responders group (progressive disease, stable disease or partial response). RESULTS: Compared to good-responders, subjects of poor-responder group showed significantly lower values of interim-ADC, ΔADC, and Δ%ADC (all P < 0.05). To distinguish between good and poor responders, the optimal cutoff values of interim-ADC, ΔADC, and Δ%ADC were determined to be 1.067 × 10-3 mm2/sec, 0.209 × 10-3 mm2/sec, and 30.74 % using the ROC curve, with corresponding sensitivities of 83.78 %, 86.49 %, 75.68 %, and specificities of 88.37 %, 86.49 %, 75.68 %, respectively. Multivariate logistic regression revealed that the baseline tumor diameter and interim-ADC were significant prognostic factors for treatment response with an odds ratio (OR) of 0.105 (95 % confidence interval [95 % CI] 0.018-0.616) for baseline tumor diameter and 42.896 (95 % CI 8.205-224.262) for interim-ADC. CONCLUSION: The interim-ADC value and baseline tumor diameter surfaced as possible indicative factors for predicting the response to RT in patients with LACC.
引用
- Liang C, Wang W, Yang G, et al. Utility of interim apparent diffusion coefficient value in predicting treatment response among patients with locally advanced cervical cancer treated with radiotherapy. Clin Transl Radiat Oncol. 2024. PMID: 39192879. doi:10.1016/j.ctro.2024.100827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。